The future of healthcare in Europe is at a critical juncture, with a pressing need to reevaluate how resources are allocated. The current model, heavily skewed towards treating illnesses, is not only unsustainable but also fails to address the root causes of many health issues.
The Prevention Paradox
One of the most striking revelations is the stark contrast between the EU's spending on care versus prevention. An alarming 80% of the budget is dedicated to managing diseases, while a mere 3-6% is allocated to preventing them. This imbalance, as Olivér Várhelyi, the EU's health commissioner, rightly points out, needs to be addressed if we are to make any meaningful progress.
A Crisis of Chronic Diseases
The focus on acute treatment has led to a situation where chronic diseases, like cardiovascular disease (CVD), remain a leading cause of death across the EU. Despite medical advancements, CVD accounts for a staggering 1.7 million fatalities annually and an estimated economic burden of €282 billion. What's even more concerning is that experts believe up to four-fifths of these cases could be prevented with existing interventions.
The Need for a Paradigm Shift
Birgit Beger, from the European Heart Network, advocates for a fundamental reorientation of European health policy. This includes stricter tobacco controls, creating healthier food environments, and implementing broader early detection programs. The current system, designed primarily for acute treatment, is simply not equipped to tackle the rising tide of chronic diseases.
A Polycrisis Demanding Structural Reform
Fraser Goodwin, representing patient associations, describes the situation as a "polycrisis" - a complex interplay of aging demographics, chronic diseases, climate change, and antimicrobial resistance. He argues that targeted fixes are no longer sufficient; what's needed is a complete structural reform. Goodwin proposes repositioning primary care as the frontline of prevention and early diagnosis, a strategy that could revolutionize how we approach healthcare.
The Role of Industry and Innovation
While the focus is rightly on prevention, industry representatives like Alexander Natz from EUCOPE caution against taking pharmaceutical innovation for granted. Geopolitical uncertainties and regulatory complexities could divert investment away from Europe, impacting the development of new treatments and therapies. Natz calls for a collaborative approach, urging policymakers to view industry as a partner in solving systemic healthcare challenges.
A Fiscal Wake-Up Call
The fiscal implications of continuing to underfund prevention are becoming increasingly clear. As Várhelyi suggests, the question is no longer about affordability but about the very structure of our healthcare systems. European governments must ask themselves if they can afford to continue structuring healthcare around illness rather than prevention.
Conclusion: A Call to Action
The time has come for a rebalancing act. Europe must invest more in prevention, not just for financial sustainability but also for the health and well-being of its citizens. This shift requires a collective effort, involving policymakers, patient groups, industry, and healthcare professionals. Only then can we hope to create a healthcare system that truly prioritizes health and prevents diseases before they occur.
